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Abstract
AIM
To investigate death for liver failure and for tumor 
recurrence as competing events after hepatectomy of 
hepatocellular carcinoma.
METHODS
Data from 864 cirrhotic Child-Pugh class A consecu-
tive patients, submitted to curative hepatectomy 
(1997-2013) at two tertiary referral hospitals, were used 
for competing-risk analysis through the Fine and Gray 
method, aimed at assessing in which circumstances 
the oncological benefit from tumour removal is greater 
than the risk of dying from hepatic decompensation. 
To accomplish this task, the average risk of these 
two competing events, over 5 years of follow-up, was 
calculated through the integral of each cumulative 
incidence function, and represented the main com-
parison parameter. 
RESULTS
Within a median follow-up of 5.6 years, death was 
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attributable to tumor recurrence in 63.5%, and to liver 
failure in 21.2% of cases. In the first 16 mo, the risk 
of dying due to liver failure exceeded that of dying due 
to tumor relapse. Tumor stage only affects death from 
recurrence; whereas hepatitis C infection, Model for 
End-stage Liver Disease score, extent of hepatectomy 
and portal hypertension influence death from liver 
failure (P  < 0.05 in all cases). The combination of these 
clinical and tumoral features identifies those patients in 
whom the risk of dying from liver failure did not exceed 
the tumour-related mortality, representing optimal 
surgical candidates. It also identifies those clinical 
circumstances where the oncological benefit would be 
borderline or even where the surgery would be harmful. 
CONCLUSION
Having knowledge of these competing events can 
be used to weigh the risks and benefits of hepatic 
resection in each clinical circumstance, separating 
optimal from non-optimal surgical candidates.
Key words: Hepatocellular carcinoma; Liver failure; 
Hepatic resection; Survival; Competing risk; Tumour 
recurrence
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Optimal candidates for hepatectomy should 
benefit from the tumour removal that encompasses 
the risk of dying from post-operative liver function 
worsening and failure. This means that when evaluating 
patients for surgery, the competing risks of tumour-
related death and of liver failure have to be weighed 
against each other, and considered from the point of 
view of available alternative therapies. In the present 
study, a large cohort of Child-Pugh class A cirrhotic 
patients submitted to curative (R0) hepatic resection 
for hepatocellular carcinoma was analysed to provide a 
competing-risk analysis of these two competing events.
Cucchetti A, Sposito C, Pinna AD, Citterio D, Cescon M, 
Bongini M, Ercolani G, Cotsoglou C, Maroni L, Mazzaferro 
V. Competing risk analysis on outcome after hepatic resection 
of hepatocellular carcinoma in cirrhotic patients. World J 
Gastroenterol 2017; 23(8): 1469-1476  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v23/i8/1469.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v23.i8.1469
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most 
common cancers worldwide[1]. It often arises on 
the background of cirrhosis, making its treatment 
completely different from other liver malignancies 
because of the conflicting needs of being oncologically 
appropriate and of preserving hepatic function. In 
this regard, a careful preoperative evaluation of both 
tumour burden and functional reserve is essential in 
order to select candidates that will most benefit from 
surgery[2]. The balance between tumour stage, hepatic 
curtailment needed to curatively remove the tumour, 
and the hepatic reserve is critical to obtain a survival 
benefit, avoiding a pointless oncological outcome, 
postoperative liver failure, progressive hepatic dete­
rioration and, ultimately, patient premature death. 
Having these aspects as determinants, hepatic resection 
is typically indicated in patients able to achieve a 
significant oncologic benefit from surgery, with low 
or null probabilities of experiencing liver function 
worsening[3]. Cirrhotic patients resected for HCC mainly 
die due to recurrence of the tumour consequences, 
and/or complications of end­stage liver disease. This 
means that when evaluating patients for surgery, the 
competing risks of tumour­related death and of liver 
failure have to be weighed against each other, and 
considered from the point of view of available alternative 
therapies. Having knowledge of these aspects can help 
in identifying optimal surgical candidates as well as in 
recognizing sub­optimal and/or non­optimal candidates 
who will most benefit from other therapies. 
Common statistical techniques for time­to­event 
analysis, including cancer­specific survival, focus on 
failure­time data with a single type of failure (even if 
composite such as disease­free survival), are not able to 
capture competing risks arising when a failure can result 
from one of several causes and one cause precludes 
the others[4,5]. Competing risk analysis can more 
adequately capture the real cause­specific survivals 
of HCC cirrhotic patients submitted to hepatectomy. 
However, at present, no data are currently available on 
the competing risk of these two main end­events. The 
aim of the present study was to analyze the competing­
risk of dying from tumour recurrence or liver failure in 
a cohort of cirrhotic patients, belonging to Child­Pugh 
class A, submitted to curative hepatic resection, and to 
investigate prognostic factors, taking into consideration 
the competing nature of these two events.
MATERIALS AND METHODS
Study population
Prospectively collected data from two Western centres 
with similar volumes, expertise and management 
strategy for HCC (Fondazione IRCCS ­ Istituto Nazionale 
Tumori, Milan, Italy and S.Orsola­Malpighi Hospital, 
Bologna, Italy) were reviewed, and patients submitted 
to curative resection (R0) of a pathologically proven 
HCC between 1997 and 2013 were identified (patients 
with R1 or R2 margin positive resection were excluded). 
Approval for conducting the study was obtained from 
the institutional review board at both centres. The study 
population selection was focused on patients with well­
preserved liver function, since they commonly represent 
typical candidates for hepatic resection. Consequently, 
only patients belonging to Child­Pugh class A were 
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retained for the analysis. None of the patients in the 
study group was treated as an emergency; none had 
macroscopic tumour portal vein invasion, invasion of 
adjacent organs or spread to the lymph nodes of the 
hepatic hilum. The final study population consisted 
of 864 consecutive Child­Pugh class A cirrhotic 
patients submitted to curative (R0) hepatectomy. 
Presence of clinical signs of portal hypertension (PHT) 
was not considered an absolute contraindication for 
hepatectomy[6]. Thus, the study cohort also includes 
patients with total bilirubin > 1 mg/dL and/or with a 
platelet count < 100000/mL and/or with oesophageal 
varices at endoscopy, namely, when tumour resection 
was judged to provide a greater benefit than other 
available options such as liver transplantation, and loco­
regional or systemic therapies.
The following variables were recorded for each 
patient: age, sex, aetiology of underlying liver disease, 
presence of oesophageal varices, main serological 
parameters (total bilirubin, creatinine, international 
normalized ratio, albumin, platelets count), and main 
tumour radiological characteristics (number and 
size of lesions). Presence of PHT was defined as the 
presence of oesophageal varices or a platelet count 
< 100000/mL[3]. The extent of the hepatectomy was 
based on the International Hepato­Pancreato­Biliary 
Association Classification[7]. Tumours were staged 
on the basis of preoperative imaging, according to 
the United Network for Organ Sharing (UNOS)­TNM 
classification[8]. 
Following discharge, all patients were observed 
periodically at follow­up to exclude possible recurrence 
of HCCs: biochemical liver function tests, serum 
α­fetoprotein level measurement, and ultrasound 
were conducted 3 and 6 mo after discharge and then 
according to an annual or semi­annual surveillance 
program in the more recent period[9]. Recurrence was 
diagnosed on the basis of HCC diagnosis guidelines 
released during the study period. None of the patients 
in this study group received adjuvant chemotherapy. 
Patients presenting recurrence were managed with 
various therapeutic modalities, including re­resection, 
when possible, and salvage liver transplantation, for 
selected patients with transplantable recurrence. The 
patient selection criteria for second hepatic resection 
were the same as for primary resection. Patients with 
non­resectable recurrence, and not suitable for liver 
transplant, were submitted to loco­regional therapies. 
From the end of 2008, Sorafenib therapy was also 
adopted, either alone or in combination with loco­
regional approaches. 
Statistical analysis 
Continuous data are reported as median and inter­
quartile ranges; categorical data as counts and percen­
tages. Patient survival was measured from the date 
of hepatic resection until death or the date of the last 
follow­up. The cause of death was recorded considering 
that patients would have died because of the tumour 
in the presence of a disseminated extra­ and/or intra­
hepatic tumour recurrence, including also those cases 
where liver function worsened as a consequence of 
tumour spread (i.e., liver involvement > 50% and/or 
development of tumour portal vein invasion). On the 
contrary, patients would have likely died because of 
liver failure (and/or its complications) in the absence 
of tumour recurrence and in the presence of clinical 
signs of end­stage liver disease, or, in cases where 
recurrence was diagnosed, in all those cases where the 
burden of tumour relapse did not justify liver failure 
(i.e., progressive liver worsening in the presence of 
small recurrences). Controversial cases were discussed 
between authors Cucchetti A and Sposito C. Cases 
not fulfilling these criteria were recorded as other 
causes of death. Follow­up ended at June 2015. 
Patients submitted to salvage transplantation were 
censored the day prior to transplant. Survival rates, 
observed after surgery, were obtained by plotting 
Kaplan­Meier curves. Cumulative incidences of the 
competing events of interest were calculated using 
the Fine and Gray competing risks approach using 
the STATA syntax stcrreg (StataCorp. Stata Statistical 
Software: Release 12.)[10]. Factors identified having a p 
< 0.10 on simple (univariate) competing risk analysis 
were entered into a multivariable regression model. 
A backward stepwise variable­selection process was 
adopted to identify independent predictors of death 
for tumour recurrence or for liver failure. A p value 
< 0.05 was considered statistically significant in all 
the analyses. The cumulative incidence of death for 
tumour relapse or hepatic failure was thus calculated 
for each combination of independent variables. The 
area under the curve of cumulative incidence over 
time was then calculated using trapezoidal rule and 
divided by time so it was expressed as average risk 
within the first 5 years from surgery. Differences 
between these incidences were compared through 
standardized differences (d) calculation, a measure 
of the effect size[11]. In particular, d values < |0.1| 
indicated very small differences between the means; 
d values between |0.1| and |0.3| indicated small 
differences, d values between |0.3| and |0.5| indicated 
moderate differences, and d values > |0.5| indicated 
considerable differences[12].
RESULTS
Baseline characteristics of the 864 cirrhotic patients, 
all belonging to Child ­ Pugh class A forming the study 
population, are reported in Table 1. The median age 
was 66.7 years, ranging between 18 and 85 years, 
most of the patients were hepatitis C positive (62.3%), 
had a single tumour (78.2%), were within UNOS­T1/
T2 stage (70.6%), and were submitted to the removal 
of one Couinaud segment or less (sub­segmentectomy) 
(72.3%). 
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cumulative incidence of death due to tumour recurrence 
or due to liver failure are reported in Table 2. Tumour 
stage and extension of hepatectomy were predictors 
of death due to tumour relapse (p = 0.002 and 0.042, 
respectively). Regarding the cumulative incidence of 
death attributable to liver failure, hepatitis C infection 
(p = 0.032), Model for End­stage Liver Disease 
(MELD) score (p = 0.001) and PHT (p = 0.029) were 
significantly related to the predicted risk of dying from 
liver failure.
For completeness of results, the same analysis was 
conducted for other causes of death but none of the 
variables analysed was found to be significantly related 
to death for causes other than tumour recurrence or 
liver failure; thus, detailed results were omitted.
Prediction of competing events incidences
Results from multivariable competing risk analysis 
are reported in Table 3. Tumour stage only affects 
death due to recurrence (p = 0.001) whereas hepatitis 
C positivity (p = 0.046), MELD score (p = 0.001), 
extension of hepatectomy (p = 0.019) and PHT (p = 
0.024) influence death as a result of liver failure. 
A summary of possible combinations of clinical and 
tumoral variables is reported in the Figure 2. Results 
are reported as average risk over 5 years of follow­
up, predicted by the multivariable regression model 
(the integer of the cumulative incidences over time 
divided by time) and were adjusted for the distribution 
of hepatitis C positive patients in the present study 
population (62.3%). The threshold for positive 
oncologic surgical benefit of liver resection (positive 
d­values) widens as the T stage progresses, while 
HCC resectability of HCC in cirrhosis becomes less 
achievable with the progression of liver dysfunction. 
Some examples can help to clarify this figure. A 
patient with a T1 tumour has an average annual risk 
of dying from cancer of 5.1% and a corresponding 
risk of dying from liver failure of 1.8%, provided there 
are no clinical signs of PHT, the patient has a MELD 
score < 9 and the tumour is removable with a wedge 
or a segmentectomy (d = 0.182: positive benefit). If 
the removal of the tumour requires a more extended 
hepatectomy and/or there are clinical signs of PHT, the 
risk of dying from liver failure increases to 3.2/3.3% 
(d < 0.10: borderline benefit), thus nullifying the 
oncologic surgical benefit. A patient with a T2 tumour 
has an annual average risk of dying from cancer of 
7.9% and, in the presence of a MELD score > 10, 
clinical signs of PHT and the need for a wedge or a 
segmentectomy, a corresponding risk of dying of liver 
failure of 14.6%; thus, the risk of dying from liver 
failure exceeds the oncologic surgical benefit (d = 
­0.213: negative effect size).
DISCUSSION
Despite the increasing incidence of HCC, the curative 
During a median follow­up of the whole cohort of 5.6 
years (range: 1 d­13 years), 489 patients experienced 
tumour recurrence (56.6%) and 334 patients died 
(38.7%). Death was attributable to tumour recurrence 
in 212 patients (63.5% of causes of death) and to 
liver failure in 71 patients (21.2%). The median time 
between tumor recurrence and death was 1.4 years. 
In 51 patients, the cause of death was not attributable 
to either of these two events (15.3%). The 30­d 
and 90­d post­operative death rates were 1.0% and 
2.4%, respectively. The 1­, 3­, 5­ and 10­year patient 
survival probabilities were 90.9%, 70.9%, 54.9% and 
29.0%. 
Competing risk analysis
Competing risk analysis on cause of death for the 
entire study population is reported in Figure 1. As can 
be noted, in the first 16 mo, the predicted risk of dying 
due to liver failure exceeds that of dying because of 
tumour recurrence. Afterwards, most deaths were 
attributable to tumour relapse whereas liver failure 
mortality remained roughly stable through subsequent 
years, namely between 4.4% at 1 year and 9.1% at 5 
years.
Relationships between clinical variables and the 
Table 1  Characteristics of the study population of cirrhotic 
patients, belonging to Child - Pugh class A, submitted to 
curative hepatectomy of hepatocellular carcinoma n  (%)
n = 864
Age (yr) 67 (61- 72)
   ≥ 67 yr 432 (50.0)
Gender male 678 (78.5)
Anti-HCV positive 538 (62.3)
HBsAg positive 197 (22.8)
Alcohol/other 120 (13.9)
Creatinine (mg/dL) 0.90 (0.80-1.04)
Albumin (g/L) 4.0 (3.7-4.3)
Bilirubin (mg/dL) 0.85 (0.64-1.19)
INR 1.13 (1.07-1.22)
Platelet count (× 103/mL) 142 (102-186)
   < 100.000/mL 202 (23.4)
MELD score 9 (8-10)
   < 9 428 (49.5)
   9-10 298 (34.5)
   > 10 138 (16.0)
Oesophageal varices 216 (25.0)
Tumour size (cm) 3.5 (2.3-5.0)
Single nodule 676 (78.2)
UNOS Stage
   T1 84 (9.7)
   T2 527 (61.0)
   T3 237 (27.4)
   T4a 16 (1.9)
Extension of hepatectomy
   Wedge/segmentectomy 625 (72.3)
   Bisegmentectomy 146 (16.9)
   Three or more segments 93 (10.8)
Continuous variables are reported as medians and interquartile ranges. 
Tumour features are radiological: 610 patients were within Milan criteria 
(70.6%). UNOS: United Network for Organ Sharing.
Cucchetti A et al . Competing risk after hepatectomy for HCC
1473 February 28, 2017|Volume 23|Issue 8|WJG|www.wjgnet.com
approach of hepatic resection remains underused 
and at times ignored. Recent data from the American 
College of Surgeons National Cancer Data Base 
showed that even if hepatic resection was associated 
with a significant increase in survival among patients 
with AJCC stage Ⅰ/Ⅱ HCC, only less than 40% of such 
patients were treated surgically[13]. This proportion 
increases when patients are managed in academic 
centres, probably because of a better knowledge of 
risks and benefits obtainable with hepatic resection[13]. 
The main concern in offering surgical resection to 
cirrhotic patients is represented by the need to avoid 
post­hepatectomy liver failure and persistent function 
worsening[2,3,6]. Considering that the main causes of 
death after hepatic resection are tumour relapse and 
liver failure, a comprehensive knowledge of these 
two distinct risks can help in daily clinical practice, 
especially when comparing surgical and non­surgical 
therapies[2]. The present results can help in fill this gap 
of knowledge. 
The first result showed that the risk course of the 
two competing end­events varies with the passage 
of time (Figure 1). In the mid­term following liver 
resection, namely in the first 16 mo, the risk of 
death from tumour relapse was lower than that from 
liver failure (that does not exceed 5%), confirming 
the curative value of surgery. The surgical benefit 
is clinically supported by the fact that diagnosis of 
recurrence is not associated with dismal prognosis 
as it used to be, since the improved ability to treat 
recurrence (even curatively) can significantly prolong 
survival[9]. These aspects have to be weighed against 
Table 2  Cumulative incidence of death from tumour recurrence and from liver failure resulting from competing risk analysis
Death from tumour recurrence Death from liver failure
1-year (%) 3-year (%) 5-year (%) 1-year (%) 3-year (%) 5-year (%)
Age (yr) P = 0.915 P = 0.267
   < 67 3.8 (0.9) 19.9 (2.2) 28.1 (2.6) 4.5 (1.0) 6.2 (1.2) 7.8 (1.4)
   ≥ 67 3.2 (0.8) 14.7 (1.9) 28.1 (2.8) 4.3 (1.0) 6.7 (1.3) 10.5 (1.8)
Gender P = 0.738 P = 0.287
   Male 3.6 (0.7) 17.7 (1.7) 27.7 (2.1) 4.2 (0.8) 6.6 (1.0) 8.5 (1.2)
   Female 3.4 (1.4) 15.4 (2.9) 28.2 (4.1) 5.0 (1.6) 7.2 (1.9) 11.1 (2.8)
Hepatitis C infection P = 0.838 P = 0.032
   Positive 3.7 (0.8) 15.9 (1.8) 27.4 (2.4) 5.3 (1.0) 7.5 (1.2) 10.9 (1.6)
   Negative 3.2 (1.0) 19.3 (2.5) 28.3 (3.1) 2.8 (0.9) 4.7 (1.2) 5.9 (1.5)
Portal hypertension1 P = 0.515 P = 0.029
   Absent 3.6 (0.8) 17.6 (1.8) 27.2 (2.3) 3.3 (0.8) 5.1 (1.0) 6.9 (1.2)
   Present 3.3 (1.0) 16.5 (2.3) 28.8 (3.2) 6.2 (1.4) 8.9 (1.7) 12.9 (2.2)
MELD score P = 0.760 P = 0.001
   < 9 4.2 (1.0) 16.7 (2.0) 27.7 (2.8) 1.9 (0.7) 3.3 (0.9) 5.2 (1.3)
   9-10 2.5 (0.9) 17.7 (2.5) 27.8 (3.2) 4.7 (1.2) 6.0 (1.4) 10.2 (2.1)
   > 10 3.6 (1.6) 17.3 (3.6) 27.7 (4.7) 11.0 (2.7) 16.6 (3.2) 17.9 (3.4)
UNOS T-stage P = 0.002 P = 0.597
   T1 1.0 (0.0) 7.6 (0.2) 14.5 (0.7) 1.2 (1.0) 3.2 (2.3) 10.6 (4.6)
   T2 3.0 (0.7) 15.4 (1.8) 25.0 (2.4) 4.1 (0.9) 6.7 (1.2) 8.7 (1.4)
   T3-T4a 5.8 (1.5) 26.3 (3.0) 34.6 (3.6) 6.0 (1.5) 7.8 (1.7) 9.3 (2.0)
Hepatectomy extension P = 0.042 P = 0.052
   Wedge/segmentectomy 3.2 (0.7) 15.2 (1.6) 26.7 (2.3) 3.0 (0.7) 5.5 (1.0) 8.7 (1.4)
   Two or more segments 4.4 (1.4) 22.3 (2.9) 30.7 (3.5) 8.1 (1.8) 9.0 (1.9) 10.3 (2.1)
Standard errors are reported in parentheses. 1Defined as presence of oesophageal varices and/or platelet count < 100000/mL. MELD: Model for End-stage 
Liver Disease; UNOS: United Network for Organ Sharing.
Table 3  Results from multivariable competing risk regression models
Sub-Hazard ratio 95%CI P  value
Death for tumour recurrence
   UNOS T-stage (T1 vs T2 vs T3-4a) 1.59 1.21-2.09 0.001
   Removal of more than one segment 1.08 0.76-1.51 0.667
Death for liver failure
   Hepatitis C (positive vs negative) 1.79 1.01-3.17 0.046
   Portal hypertension (present vs absent) 1.84 1.08-3.12 0.024
   MELD class (< 9 vs 9-10 vs > 10) 2.21 1.59-3.07 0.001
   Removal of more than one segment 1.89 1.11-3.21 0.019
The multivariable model included variables with a P < 0.10 of Table 2. A backward stepwise variable-selection process was selected to obtain estimates 
of non-significant variables (Removal of more than one segment for death from tumour recurrence; P = 0.667). Sub-hazard ratios were used together with 
the baseline cumulative sub-hazard function (data not reported) to predict individual risks of death for liver failure and for tumour recurrence reported in 
Figure 2.
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the risk of liver failure, which, in the absence of a liver 
transplant, still represents a diagnosis of imminent 
death. From the present results, it can be said that, 
starting from the first year onwards, the healing ability 
of surgery begins to decline and long­term risks and 
benefits should be evaluated from this time point 
onwards.
One main clinical indication that can be derived 
from the present study regards the identification 
of optimal and non­optimal candidates for liver 
surgery, even beyond conventional recommendations 
(Figure 2). It can be suggested that optimal surgical 
candidates are those patients having a long­term 
risk of dying due to tumour relapse constantly higher 
than that of dying from liver failure. In cirrhotic 
patients with a T1 tumour (single nodule < 2 cm), in 
the absence of clinical signs of PHT, MELD < 9 and 
limited extent of liver resection, namely a wedge or a 
segmentectomy, the average annual risk of dying from 
cancer is considerably higher (5.1%) than that of dying 
of liver failure (1.8%). The magnitude of the effect size 
(d = 0.182) supports the indication for surgery in this 
kind of patient, who has a tumour that is superficially 
located and easily removable with limited removal 
of liver parenchyma. In cases in which the presence 
of initial signs of liver function worsening (PHT or 
increased MELD score) or where there is a need for 
greater parenchymal removal, the risk of dying from 
liver failure starts to increase, nullifying the oncological 
benefit (effect size < 0.1) and becoming potentially 
harmful in more advanced degrees of liver dysfunction 
(negative effect size). In these cases, patients become 
non­ideal candidates for surgery, supporting the role of 
loco­regional treatments. 
Patients with a T2 tumour (single nodule 2­3 cm 
or 2­3 nodules all < 3 cm) represent the majority of 
surgical candidates[14] and it is worthy of note that in 
cases of multiple lesions these patients fall beyond 
conventional recommendations built on the Barcelona 
Clinic Liver Cancer (BCLC) staging system[3,15,16]. T2 
patients are burdened by an average annual risk of 
dying from tumour recurrence of 7.9%. From the 
comparison of the two competing risks, it can be noted 
that the oncological benefit obtainable from surgery, 
allows acceptance of a higher risk of liver failure 
(Figure 2). That is, in the presence of a T2 tumour, 
clinical signs of PHT should not represent an absolute 
contraindication to surgery (effect size > 0.1), provided 
there is a substantial normal liver function (MELD < 
9­10)[6,16,17]. In these cases, the risk of tumour­related 
death was permanently higher than that of death 
due to liver failure, supporting the concept that the 
benefit obtainable with surgery is considerably greater 
than the risk of liver failure. Conversely, a more 
advanced degree of liver dysfunction and/or the need 
for more extensive hepatectomies may turn surgery 
into a harmful treatment that can be justified by the 
possibility of a subsequent salvage transplantation: a 
resource­consuming alternative that, on top of poorly 
predictable outcome, transforms an elective strategy 
into an emergency procedure. 
Tumours still of surgical interest while belonging 
to UNOS­T3­T4a stages mostly fall within the interme­
diate stage of BCLC algorithm[3,15,18]. Resectability in 
these patients should be assessed by experienced 
surgical groups before offering trans­arterial chemo­
embolization (TACE)[18] as a (non­curative) alternative 
treatment option. These tumour stages are burdened 
by the highest risk of dying from tumour relapse, thus 
making it possible to prioritise the surgical indication, 
including also patients with PHT and MELD scores 
around 10. In fact, surgically­resectable T3­T4a pa­
tients are non­ideal candidates for resection but, as 
recently outlined in a large analysis, a patient who may 
not be an ideal candidate for resection may still have a 
better outcome than what is expected when alternative 
modalities recommended by the current guidelines are 
applied[2]. Thus, the recommended treatment modality 
for the intermediate stage represented by TACE[18] 
can be challenged by liver resection, not in all cases 
but under the specific circumstances specified above. 
Notably, in pertinent literature benchmarks, TACE has, 
in the best­case scenario, a median survival of about 
2 years[3,15,18,19], corresponding to an average risk of 
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Figure 1  Cumulative incidences of death from liver failure, tumour recurrence and other causes after curative hepatic resection for hepatocellular 
carcinoma. Of note, in the first 16 mo, the risk of dying from liver failure exceeds that of dying because of tumour recurrence, confirming the curative value of surgery.
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dying during the first 5 years of about 48%, which 
is always higher than present figures after resection 
(Figure 2). In other words, the present results support 
patients with intermediate stage HCC being offered 
liver resection when this is judged technically feasible 
in experienced centres and when the risk of dying from 
liver cancer exceeds the risk of liver failure. In all other 
instances, T3­T4a patients should remain with the 
conventional approach and be considered for TACE.
In determining the risk of dying from liver failure, 
hepatitis C infection deserves special consideration. The 
present study population encompasses a time period 
when direct antiviral agents (DAA) were not available, 
and only a small proportion of the most recently 
resected patients are currently receiving DAA. The low 
probabilities of achieving a cure for hepatitis C infection 
with standard interferon­based regimens of the past 
decades, and consequently the low probabilities of 
slowing down (or stopping) the progression of cirrhosis, 
are the reasons for its strong impact in the liver failure­
related deaths observed in the present study. Although 
somewhat optimistic, it is reasonable to think that DAA 
can, in the future, achieve control of the progression 
of cirrhosis: presuming an improvement in the pro­
gression of cirrhosis, the competing role of tumour­
related death will increase the benefit obtainable from 
hepatic resection.
Some limitations of the present study deserve 
appropriate discussion. First, it reports the experience 
from a surgical series and a comparison with non­
surgical therapies would be the ultimate goal. Such 
a comparison is advisable for future studies that 
consider the competing risks of dying from cancer 
or liver failure in relationship with other therapeutic 
modalities. However, it is not strictly necessary in the 
current analysis to have this control group: these 
surgical results can be seen as a reference point for 
other studies of TACE or ablation without all being 
assessed in the same study. Nevertheless, future 
comparative studies using a competing risk approach 
are warranted. Second, the retrospective nature of 
the present study and the policies adopted in our 
centres may have determined a surgical population 
selection not completely representative of all patients 
suffering from resectable HCC. However, as previously 
outlined[13], patients managed in academic centres are 
more frequently offered such a potentially curative 
treatment, and the present data can be considered 
representative of a tertiary level hospital experience. 
Finally, limitations of the multivariable competing risk 
regression model have also to be taken into account. 
Even if it comes from a relatively large sample size, 
the risk of over-fitting the model cannot be excluded 
and the present results require further external or 
prospective validations to confirm their validity.
In conclusion, the present study provided a first 
competing risk analysis of causes of death after 
hepatic resection of HCC that could be used as a 
reference for similar analyses conducted on alternative 
treatments such as ablation or TACE. Ideal candidates 
for hepatic resection should be represented by those 
patients having a risk of dying from tumour cancer 
that is significantly greater than the risk of dying from 
liver failure. 
COMMENTS
Background
The main concern in offering surgical resection to cirrhotic patients with 
hepatocellular carcinoma (HCC) is represented by the need to avoid post-
hepatectomy function worsening. Considering that the main causes of 
death after surgery are represented by tumour relapse and liver failure, a 
comprehensive knowledge of these two distinct competing risks can help in 
clinical practice to distinguish optimal from non-optimal surgical candidates.
Research frontiers
Ideal candidates for hepatic resection should be represented by those patients 
having a risk of dying from tumour cancer that is significantly greater than the 
risk of dying from liver failure.
Innovations and breakthroughs
This study is the first one to provide a first competing risk analysis of causes 
of death after hepatic resection of HCC. The combination of tumour size and 
number, Model for End-stage Liver Disease score, extension of hepatectomy 
required to curatively remove the tumour and the absence or presence of 
Figure 2  Comparison between the predicted average risk of dying for 
liver failure (rows) and for tumour recurrence (columns) within the first 
5 years after surgery, resulting from the competing-risk regression 
model. The average risks reported derive from: (1) the calculation of the area 
under the curves (AUC) of the risk of dying from liver failure and from tumour 
recurrence over time, predicted by the competing-risk model of Table 3; and 
(2) the division of the obtained AUCs by the time-period considered (5 years). 
Comparison between these two distinct risks is reported as effect size: values < 
|0.1| indicated very small differences between the means; values between |0.1| 
and |0.3| indicated small differences, values between |0.3| and |0.5| indicated 
moderate differences, and values > |0.5| indicated considerable differences. 
When the risk of dying of liver failure after resection is greater than that of dying 
from tumour relapse, effect size returns negative values (dark grey cells).
Risk of dying from tumour 
recurrence
Risk of dying from liver failure T1 T2 T3-T4a
PHT > 1 segment MELD % 5.1 7.9 12.2
No No < 9 1.8 0.182 0.287 0.416
No Yes < 9 3.2 0.095 0.206 0.343
Yes No < 9 3.3 0.090 0.201 0.338
No No 9-10 3.9 0.058 0.170 O.309
Yes Yes < 9 5.7 -0.027 0.087 0.229
Yes No 9-10 6.8 -0.072 0.042 0.185
No Yes 9-10 7.1 -0.084 0.030 0.173
No No > 10 9.2 -0.160 -0.047 0.097
Yes Yes 9-10 12.5 -0.263 -0.152 -0.009
Yes No > 10 14.6 -0.323 -0.213 -0.070
No Yes > 10 15.1 -0.337 -0.227 -0.085
Yes Yes > 10 25.4 -0.589 -0.483 -0.343
Positive oncologic benefit of resection
Borderline oncologic benefit of resection
Negative oncologic benefit of resection
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clinical signs of portal hypertension, identifies those patients in whom the risk of 
dying from liver failure did not exceed the tumour-related mortality, representing 
optimal surgical candidates.
Applications
Having knowledge of these competing events can be used to weigh risks 
and benefits of hepatic resection in each clinical circumstance, providing a 
benchmark to also assess the benefit achievable from non-surgical therapies, 
such as ablation or embolization. 
Terminology
Survival analysis is the analysis of data measured from a specific time of origin 
until an event of interest or a specified endpoint occurs, where every patient 
provides two pieces of information: follow-up time and status (i.e., event or 
censored endpoint). However, a patient may experience an event different from 
the event of interest. For example, a patient with HCC may die due to causes 
unrelated to his/her cancer. Such events are termed competing risk events.
Peer-review
A very interesting observation study provided a first competing risk analysis of 
causes of death after hepatic resection of HCC particular on the patients with 
Child’ A functional class. This manuscript is well written and analyzing. It should 
benefit to kind in mild that those patients having a risk of dying from cancer 
resection that significantly overcome the risk of dying from liver failure. 
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